logo image

Daclizumab information from DrugsUpdate  

See Available Brands of Daclizumab in India

Daclizumab, a humanized monoclonal antibody, and immunosuppressant is prescribed for the prevention of acute organ rejection in renal transplanted patients. Daclizumab can be administered as a combined therapy with cyclosporine and/or corticosteroids. Daclizumab lowers incidence of acute graft rejection in allograft transplanted patients.


Daclizumab is an Interleukin-2 (IL-2) receptor blocker that binds with Tac subunit of IL-2 receptor complex and thereby prevents IL-2 binding. Daclizumab binds with Tac receptors of activated lymphocytes but not in normal lymphocytes. Daclizumab inhibits IL-2 mediated lymphocyte activation and prevents graft rejection. However, the duration of drug action is still unknown.


Information not available

Daclizumab Indications / Daclizumab Uses

Information not available

Daclizumab Adverse Reactions / Daclizumab Side Effects

Daclizumab treatment is associated with development of certain malignancies including lymphoma and serious allergic reactions. Other non-serious adverse events of Daclizumab are headache, edema in the extremities, GI upset, nausea/vomiting, tremors, constipation and dizziness.


Daclizumab treatment is contraindicated in patients who are either allergic or tolerant. Daclizumab treatment should not be used in patients with chronic infections, immunosuppression and immune system disorders.

Special Precautions

Information not available

Other Drug Interactions

Daclizumab may interact with several vaccines including live vaccines. Mechanism of action of Daclizumab may impair the efficacy of vaccines including nasal influenza vaccine and oral polio vaccine.

Other Interactions

Information not available


The recommended dose of Daclizumab in pediatric patients and adults is 1 mg/kg. In accordance with body weight, Daclizumab should be administered intravenously after reconstitution with 50 ml of 0.9% sterile saline over a period of 15 minutes. Within 24 hours of organ transplantation, first dose of Daclizumab should be administered. Within two weeks, the remaining four doses should be given.


Daclizumab can be taken with or without food

List of Contraindications

Daclizumab and Pregnancy

Daclizumab and Pregnancy
USFDA pregnancy category C. Taking Daclizumab may be harmful to an unborn fetus. Consult your doctor if you are, in gestation or planning, to have a baby during Daclizumab treatment.

Daclizumab and Lactation

Nursing mothers should consult the healthcare provider before Daclizumab treatment.

Daclizumab and Children

Information not available

Daclizumab and Geriatic

Information not available

Daclizumab and Other Contraindications

Information not available


Store at 20-25°C.

Lab interference

Store at 20-25°C.

Daclizumab brands in India:


© 2011-2018 DrugsUpdate.com. Disclaimer | Site Map